Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults

References

• Leung LLK. Direct oral anticoagulants and parenteral direct thrombin inhibitors: dosing and adverse effects. In: Mannucci PM, editor.UpToDate. Waltham, MA: UpToDate Inc;[cited 2017 Jun 08].Available from: http://www.uptodate.com
   Google Scholar
• Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e44S–e88S.
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med. 2005 Sep 8;353(10):1028–1040.
   PubMed Web of Science ®Google Scholar
• Laux V, Perzborn E, Heitmeier S, et al. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost. 2009 Nov;102(5):892–899.
   PubMed Web of Science ®Google Scholar
• Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem. 2005 Sep 22;48(19):5900–5908.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998 Oct 16;82(8A):2N–9N.
   PubMed Web of Science ®Google Scholar
• Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991 May;151(5):933–938.
   PubMedGoogle Scholar
• Bajorek B. A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks. Ther Adv Drug Saf. 2011 Apr;2(2):45–58.
   PubMedGoogle Scholar
• Bo M, Grisoglio E, Brunetti E, et al. Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence. Eur J Intern Med. 2017 Jun;41:18–27.
   PubMed Web of Science ®Google Scholar
• Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007 Apr;5(4):692–699.
   PubMed Web of Science ®Google Scholar
• White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007 Feb 12;167(3):239–245.
   PubMedGoogle Scholar
• Siguret V, Gouin I, Debray M, et al. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med. 2005 Feb;118(2):137–142.
   PubMed Web of Science ®Google Scholar
• Costa GL, Ferreira DC, Valacio RA. et al. Quality of management of oral anticoagulation as assessed by time in therapeutic INR range in elderly and younger patients with low mean years of formal education: a prospective cohort study. Age Ageing. 2011 May;40(3):375–381.
   PubMed Web of Science ®Google Scholar
• Chambers S, Chadda S, Plumb JM. How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review. Int J Lab Hematol. 2010 Aug 1; 32(4):427–442.
   PubMed Web of Science ®Google Scholar
• Kim MM, Metlay J, Cohen A, et al. Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults. Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):731–736.
   PubMed Web of Science ®Google Scholar
• Ghate SR, Biskupiak J, Ye X, et al. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm. 2011 Nov;17(9):672–684.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al., ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al., ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012 Nov 13;126(20):2381–2391.
   PubMed Web of Science ®Google Scholar
• Adam SS, McDuffie JR, Ortel TL, et al. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. 2012 Dec 4;157(11):796–807.
   PubMed Web of Science ®Google Scholar
• Ntaios G, Papavasileiou V, Diener HC, et al. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke. 2012 Dec;43(12):3298–3304.
   PubMed Web of Science ®Google Scholar
• Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015 Jul 21;132(3):194–204.
   PubMed Web of Science ®Google Scholar
• Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014 May;62(5):857–864.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Gross PL. New oral anticoagulants: which one should my patient use? Hematology Am Soc Hematol Educ Program. 2012;2012:536–540.
   PubMed Web of Science ®Google Scholar
• Hirsh J, Fuster V, Ansell J, et al., American Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003 Apr 1;107(12):1692–1711.
   PubMed Web of Science ®Google Scholar
• Crouse B, Quigley S New oral anticoagulants: an economic analysis. [cited 2017 Jun 08]. Available from https://lecom.edu/new-oral-anticoagulants-an-economic-analysis/
   Google Scholar
• Liberato NL, Marchetti M. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):221–235.
   PubMed Web of Science ®Google Scholar
• Zhao YJ, Lin L, Zhou HJ, et al. Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation. Int J Cardiol. 2016;220:794–801.
   PubMed Web of Science ®Google Scholar
• Babar Z. Economic evaluation of pharmacy services. 1st ed. Cambridge, MA: Academic Press; 2016.
   Google Scholar
• Sullivan PW, Arant TW, Ellis SL, et al. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24(10):1021–1033.
   PubMed Web of Science ®Google Scholar
• Verhoef TI, Ragia G, de Boer A, et al., EU-PACT Group. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013 Dec 12;369(24):2304–2312.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Burnside G, Eriksson N, et al., EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013 Dec 12;369(24):2294–2303.
   PubMed Web of Science ®Google Scholar
• Kimmel SE, French B, Kasner SE, et al., COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013 Dec 12;369(24):2283–2293.
   PubMed Web of Science ®Google Scholar
• Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005 Apr;91(4):472–477.
   PubMed Web of Science ®Google Scholar
• Van Spall HG, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012 Nov 6;126(19):2309–2316.
   PubMed Web of Science ®Google Scholar
• Verhoef TI, Redekop WK, Darba J, et al., EU-PACT Group. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics. 2010 Jul;11(7):989–1002.
   PubMed Web of Science ®Google Scholar
• Verhoef TI, Redekop WK, Langenskiold S, et al. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenomics J. 2016 Oct;16(5):478–484.
   PubMed Web of Science ®Google Scholar
• Ghadimi K, Dombrowski KE, Levy JH, et al. Andexanet alfa for the reversal of factor Xa inhibitor related anticoagulation. Expert Rev Hematol. 2016;9(2):115–122.
   PubMed Web of Science ®Google Scholar
• Damaske DL, Baird RW. Development and implementation of a pharmacist-managed inpatient warfarin protocol. Proc (Bayl Univ Med Cent). 2005 Oct;18(4):397–400.
   PubMedGoogle Scholar
• Saokaew S, Sapoo U, Nathisuwan S, et al. Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. Int J Clin Pharm. 2012 Feb;34(1):105–112.
   PubMed Web of Science ®Google Scholar
• Saokaew S, Permsuwan U, Chaiyakunapruk N, et al. Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis. J Thromb Haemost. 2010 Nov;8(11):2418–2427.
   PubMed Web of Science ®Google Scholar
• Lee YP, Schommer JC. Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions. Am J Health Syst Pharm. 1996 Jul 1;53(13):1580–1583.
   PubMed Web of Science ®Google Scholar
• Mattaya S, Anusornsangiam W, Kanjanasilp J, et al. Outcome of pharmaceutical care in anticoagulation clinic at Roi-Et hospital, Roi-Et province, Northeastern Thailand. J Sci Technol MSU. 2008;27(1):59–67.
   Google Scholar
• Biscup-Horn PJ, Streiff MB, Ulbrich TR, et al. Impact of an inpatient anticoagulation management service on clinical outcomes. Ann Pharmacother. 2008 Jun;42(6):777–782.
   PubMed Web of Science ®Google Scholar
• Munjamroon Y, Suttajit S, Tammarat T, et al. Clinical outcomes of warfarin monitoring in outpatients at Nakorn Phanom Hospiatal. J Sci Technol MSU. 2007;26:38–46.
   Google Scholar
• Zed PJ, Filiatrault L. Clinical outcomes and patient satisfaction of a pharmacist-managed, emergency department-based outpatient treatment program for venous thromboembolic disease. Cjem. 2008 Jan;10(1):10–17.
   PubMedGoogle Scholar
• Krittathanmakul S, Silapachote P, Pongwecharak J, et al. Effects of pharmacist counseling on outpatients receiving warfarin at Songklanagarind Hospital. Songkla Med J. 2006;24(2):93–99.
   Google Scholar
• Macik BG. The future of anticoagulation clinics. J Thromb Thrombolysis. 2003 Aug-Oct;16(1–2):55–59.
   PubMedGoogle Scholar
• Schalekamp T, de Boer A. Pharmacogenetics of oral anticoagulant therapy. Curr Pharm Des. 2010;16(2):187–203.
   PubMed Web of Science ®Google Scholar
• Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009 Jan 22;113(4):784–792.
   PubMed Web of Science ®Google Scholar
• Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005 Oct 1;106(7):2329–2333.
   PubMed Web of Science ®Google Scholar
• Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005 Jul 1;106(1):135–140.
   PubMed Web of Science ®Google Scholar
• Schalekamp T, Brassé BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther. 2007 Feb;81(2):185–193.
   PubMed Web of Science ®Google Scholar
• Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999 Feb 27;353(9154):717–719.
   PubMed Web of Science ®Google Scholar
• D’Andrea G, D’Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005 Jan 15;105(2):645–649.
   PubMed Web of Science ®Google Scholar
• Klein TE, Altman RB, Eriksson N, et al., International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 Feb 19;360(8):753–764.
   PubMed Web of Science ®Google Scholar
• Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther. 2010 May;87(5):572–578.
   PubMed Web of Science ®Google Scholar